New York, USA, April 13, 2026 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
The eosinophilic esophagitis market is witnessing steady growth, primarily driven by the increasing awareness leading to standardized diagnosis and high relapse rates that continue to fuel ongoing treatment demand. Additionally, the expected launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen), APT-1011 (fluticasone propionate) (Ellodi Pharmaceuticals), IRL201104 (Revolo Biotherapeutics), Vonoprazan (VOQUEZNA) (Phathom Pharmaceuticals), and others will further propel the market growth.
Recently published Eosinophilic Esophagitis Market Insights report includes a comprehensive understanding of current treatment practices, eosinophilic esophagitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Eosinophilic Esophagitis Market Summary
- The market size for eosinophilic esophagitis was found to be USD 647 million in the US in 2025.
- The United States accounted for the largest eosinophilic esophagitis treatment market size in 2025, i.e 72%, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- In 2025, Proton Pump Inhibitor (PPIs) treatment for EoE generated approximately USD 346 million in revenue across the 7MM countries.
- In the 7MM, the US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2025, with around 512,000 cases; these numbers are expected to increase during the forecast period.
- Key eosinophilic esophagitis companies, including AstraZeneca, Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, and others, are actively working on innovative eosinophilic esophagitis drugs.
- Some of the key eosinophilic esophagitis therapies in clinical trials include Tezepelumab (TEZSPIRE), APT-1011 (fluticasone propionate), IRL201104, Vonoprazan (VOQUEZNA), Solrikitug (NSI-8226), ESO-101, Viaskin milk (DBV-135), EP-104GI, and others. These novel eosinophilic esophagitis therapies are anticipated to enter the eosinophilic esophagitis market in the forecast period and are expected to change the market.
Discover eosinophilic esophagitis market size 2036 @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market
Key Factors Driving the Growth of the Eosinophilic Esophagitis Market
- Rising EoE Diagnosed Prevalence: There were nearly 511,000 diagnosed cases of EoE in the US in 2025. Due to increased disease awareness and standardized diagnostic criteria, this number is projected to increase by 2036, highlighting a continuing trend in diagnosed prevalence that may be influenced by improved surveillance and management practices over time.
- Growing Burden of Allergic Disorders: The surge in food and environmental allergies, key triggers of EoE, is significantly fueling market demand. Conditions like atopic disorders and chronic respiratory diseases further increase susceptibility, driving diagnosis and treatment rates.
- Improved Diagnostics and Awareness: Advancements in diagnostic techniques such as endoscopy and biopsy, along with increasing awareness among healthcare professionals, are enabling earlier and more accurate diagnosis, expanding the treated patient population.
- Evolving Competitive Landscape in EoE Therapeutics: The dynamics of the EoE market are expected to change in the coming years due to the launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen), APT-1011 (fluticasone propionate) (Ellodi Pharmaceuticals), IRL201104 (Revolo Biotherapeutics), Vonoprazan (VOQUEZNA) (Phathom Pharmaceuticals), Solrikitug (NSI-8226) (Uniquity Bio), ESO-101 (EsoCap AG), Viaskin milk (DBV-135) (DBV Technologies), EP-104GI (Eupraxia Pharmaceuticals), and others.
- Next-Generation Delivery Approaches: Diverse and innovative delivery approaches address key limitations of existing therapies, including EP-104GI’s once-yearly submucosal injection, which may significantly reduce treatment burden and improve adherence.
- APT-1011’s First-Mover Edge with Fast Track Designation: APT-1011’s FTD positions it for potentially faster review and earlier market entry, creating first-mover advantage among next-generation therapies.
Aparna Thakur, Assistant Project Manager, Forecasting at DelveInsight, said that emerging therapies that reduce dosing frequency or improve ease of administration may capture patients with adherence challenges or inadequate response to current options.
Eosinophilic Esophagitis Market Analysis
- First-line management of EoE generally begins with proton pump inhibitors (PPIs), though a substantial proportion of patients fail to achieve sufficient symptom control.
- Consequently, treatment often escalates to swallowed topical corticosteroids or biologics, along with non-drug interventions such as elimination diets and esophageal dilation, underscoring the importance of a multimodal therapeutic strategy.
- At present, three therapies are approved for EoE: budesonide oral dispersible tablets (JORVEZA) (Europe, 2018, for adults), dupilumab (DUPIXENT), the first and only biologic (US, 2022; approved for patients aged ≥1 year and also in Europe), and budesonide oral suspension (EOHILIA) (US, 2024, for patients aged ≥11 years).
- A robust pipeline is being advanced by companies such as AstraZeneca, Amgen, Uniquity Bio, Ellodi Pharmaceuticals, EsoCap, and Revolo Biotherapeutics, among others, with candidates expected to significantly influence the EoE market over the forecast period.
- Prominent mechanisms under evaluation include thymic stromal lymphopoietin inhibitors (e.g., TEZSPIRE, Solrikitug), glucocorticoid receptor agonists (APT-1011, ESO-101, EP-104GI), and immunomodulators (e.g., IRL201104).
- Many investigational therapies have secured Orphan Drug Designation (ODD) from the US FDA, including VELSIPITY, TEZSPIRE, APT-1011, ESO-101, and IRL201104. Notably, APT-1011 is the only candidate to have received Fast Track Designation (FTD) and is anticipated to be among the first to enter the market, offering a potential competitive advantage.
- Despite clinical setbacks for AstraZeneca’s FASENRA and Celldex’s barzolvolimab, agents such as Allakos’s lirentelimab have gained momentum and are emerging as key contenders to compete with DUPIXENT in the evolving EoE treatment landscape.
Learn more about the EoE approved drugs list @ Eosinophilic Esophagitis Treatment Market
Eosinophilic Esophagitis Competitive Landscape
Some of the eosinophilic esophagitis drugs under development include Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen), APT-1011 (fluticasone propionate) (Ellodi Pharmaceuticals), IRL201104 (Revolo Biotherapeutics), Vonoprazan (VOQUEZNA) (Phathom Pharmaceuticals), Solrikitug (NSI-8226) (Uniquity Bio), ESO-101 (EsoCap AG), Viaskin milk (DBV-135) (DBV Technologies), EP-104GI (Eupraxia Pharmaceuticals), and others.
AstraZeneca and Amgen’s Tezepelumab is a novel monoclonal antibody. It targets thymic stromal lymphopoietin (TSLP), an upstream epithelial cytokine that plays a central role in triggering and sustaining multiple inflammatory pathways. By inhibiting TSLP, tezepelumab addresses the underlying drivers of allergic, eosinophilic, and other epithelial inflammatory responses associated with conditions such as severe asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), along with other related disorders.
In its Q3 2025 update presented in November 2025, AstraZeneca indicated that results from the CROSSING trial evaluating tezepelumab in Eosinophilic Esophagitis (EoE) are expected in the latter half of 2026. Earlier, in October 2021, the therapy received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for EoE treatment.
Ellodi Pharmaceuticals’ APT-1011 is an innovative, once-daily orally disintegrating tablet (ODT) developed to deliver fluticasone propionate directly to the esophageal lining, providing localized anti-inflammatory effects while minimizing systemic exposure. Following the successful outcomes of the FLUTE 1 (Phase IIb) and FLUTE 2 (Phase III) trials, the FLUTE 3 study, a second Phase III trial, is currently underway.
In May 2024, Ellodi Pharmaceuticals presented findings from the FLUTE-2 Phase III trial at Digestive Disease Week (DDW) 2024 Annual Scientific Meeting, highlighting the efficacy of APT-1011 in EoE. The therapy has been granted Orphan Drug Designation by both the FDA and the European Medicines Agency, along with Fast Track Designation (FTD) from the FDA in 2021. These designations were supported by clinical data demonstrating histological remission, symptomatic relief after 12 weeks of induction therapy, and sustained benefits over long-term treatment.
Revolo Biotherapeutics’ IRL201104 represents a first-in-class peptide designed to re-establish immune balance by modulating both regulatory and effector immune pathways. In August 2025, Revolo Biotherapeutics announced plans to fast-track the clinical development of a sublingual tablet formulation of IRL201104, administered under the tongue.
The anticipated launch of these emerging eosinophilic esophagitis therapies are poised to transform the Eosinophilic Esophagitis market landscape in the coming years. As these cutting-edge eosinophilic esophagitis therapies continue to mature and gain regulatory approval, they are expected to reshape the eosinophilic esophagitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about novel treatments for EoE, visit @ Eosinophilic Esophagitis Medication
Recent Developments in the Eosinophilic Esophagitis Market
- In January 2026, Phantom Pharmaceuticals anticipates topline data in 2027 from its Phase II clinical trial (pHalcon-EoE-201) in patients with EoE.
- In January 2026, Eupraxia Pharmaceuticals announced positive 12-week and 36-week tissue health data from its ongoing Phase Ib/IIa part of the RESOLVE trial evaluating EP-104GI for the treatment of EoE.
- In November 2025, the second set of 52-week follow-up data from the ongoing Phase Ib/IIa RESOLVE trial evaluating a single administration of EP-104GI was announced for the treatment of EoE.
- In November 2025, the first patient had been dosed in its Phase II clinical trial (pHalcon-EoE-201) evaluating vonoprazan tablets as an investigational treatment for EoE in adults.
What is Eosinophilic Esophagitis?
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus characterized by the accumulation of eosinophils in the esophageal lining. It is primarily triggered by food allergens and, in some cases, environmental allergens, leading to symptoms such as difficulty swallowing, food impaction, chest discomfort, and persistent heartburn that does not respond well to conventional acid-suppressive therapies. Over time, untreated EoE can cause esophageal remodeling, including fibrosis and strictures, which further impair swallowing. The condition is commonly associated with other atopic disorders such as asthma, allergic rhinitis, and eczema. Diagnosis typically involves endoscopic evaluation and biopsy, while management includes dietary modifications, proton pump inhibitors, and topical corticosteroids to reduce inflammation and prevent disease progression.
Eosinophilic Esophagitis Epidemiology Segmentation
The eosinophilic esophagitis epidemiology section provides insights into the historical and current eosinophilic esophagitis patient pool and forecasted trends for the leading markets. In the EU4 and the UK, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 395,000 cases reported in 2025.
The eosinophilic esophagitis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis
- Gender-specific Cases of Eosinophilic Esophagitis
- Age-specific Cases of Eosinophilic Esophagitis
- Treated Cases of Eosinophilic Esophagitis
Download the report to understand current treatment for eosinophilic esophagitis @ Eosinophilic Esophagitis Treatment Options
| Eosinophilic Esophagitis Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Eosinophilic Esophagitis Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Eosinophilic Esophagitis Market CAGR (US) | 13.2% |
| Eosinophilic Esophagitis Market Size in 2025 (US) | USD 647 Million |
| Key Eosinophilic Esophagitis Companies | AstraZeneca, Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Dr. Falk Pharma GmbH, Takeda, and others |
| Key Eosinophilic Esophagitis Therapies | Tezepelumab (TEZSPIRE), APT-1011 (fluticasone propionate), IRL201104, Vonoprazan (VOQUEZNA), Solrikitug (NSI-8226), ESO-101, Viaskin milk (DBV-135), EP-104GI, DUPIXENT, JORVEZA, EOHILIA, and others |
Scope of the Eosinophilic Esophagitis Market Report
- Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and emerging therapies
- Eosinophilic Esophagitis Market Dynamics: Conjoint Analysis of Emerging Eosinophilic Esophagitis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Eosinophilic Esophagitis Market Unmet Needs, KOL’s views, Analyst’s views, Eosinophilic Esophagitis Market Access and Reimbursement
Discover more about eosinophilic esophagitis drugs in development @ Eosinophilic Esophagitis Clinical Trials
Table of Contents
| 1 | Eosinophilic Esophagitis Market Key Insights |
| 2 | Eosinophilic Esophagitis Market Report Introduction |
| 3 | Executive Summary |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | Eosinophilic Esophagitis Market Overview at a Glance |
| 6.1 | Clinical Landscape Analysis (By Mechanism of Action [MoA] and Molecule Type) |
| 6.2 | Market Share of EoE by Therapies (%) in the 7MM in 2025 |
| 6.3 | Market Share of EoE by Therapies (%) in the 7MM in 2036 |
| 7 | Disease Background and Overview of Eosinophilic Esophagitis |
| 7.1 | Introduction |
| 7.2 | Symptoms |
| 7.3 | Causes and Risk Factors |
| 7.4 | Pathophysiology |
| 7.5 | Diagnosis |
| 7.6 | Diagnostic Guidelines |
| 8 | Treatment of Eosinophilic Esophagitis |
| 9 | Eosinophilic Esophagitis: 7MM Analysis |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Total Diagnosed Prevalent Cases of EoE in the 7MM |
| 9.4 | The United States |
| 9.4.1 | Total Diagnosed Prevalent Cases of EoE in the United States |
| 9.4.2 | Gender-specific Diagnosed Prevalent Cases of EoE in the United States |
| 9.4.3 | Age-specific Diagnosed Prevalent Cases of EoE in the United States |
| 9.4.4 | Total Treated Cases of EoE in the United States |
| 9.5 | EU4 and the UK |
| 9.6 | Japan |
| 10 | Patient Journey of Eosinophilic Esophagitis |
| 11 | Marketed Eosinophilic Esophagitis Therapies |
| 11.1 | Competitive Landscape: Marketed Therapies |
| 11.2 | Dupilumab (DUPIXENT): Sanofi/Regeneron Pharmaceuticals |
| 11.2.1 | Product Description |
| 11.2.2 | Regulatory Milestones |
| 11.2.3 | Other Developmental Activities |
| 11.2.4 | Clinical Development |
| 11.2.4.1 | Clinical Trials Information |
| 11.2.5 | Summary of Pivotal Trials |
| 11.2.6 | Safety and Efficacy |
| 11.2.7 | Analyst’s View |
| 11.3 | Budesonide ODT (JORVEZA): Dr. Falk Pharma GmbH |
| 11.4 | Budesonide Oral Suspension (EOHILIA): Takeda |
| 12 | Emerging Eosinophilic Esophagitis Therapies |
| 12.1 | Competitive Landscape: Emerging Therapies |
| 12.2 | Tezepelumab (TEZSPIRE): AstraZeneca and Amgen |
| 12.2.1 | Product Description |
| 12.2.2 | Other Developmental Activities |
| 12.2.3 | Clinical Development |
| 12.2.3.1 | Clinical Trials Information |
| 12.2.4 | Analyst’s View |
| 12.3 | APT-1011 (fluticasone propionate): Ellodi Pharmaceuticals |
| 12.4 | IRL201104: Revolo Biotherapeutics |
| 12.5 | Vonoprazan (VOQUEZNA): Phathom Pharmaceuticals |
| 12.6 | Solrikitug (NSI-8226): Uniquity Bio |
| 12.7 | ESO-101: EsoCap AG |
| 12.8 | Viaskin milk (DBV-135): DBV technologies |
| 12.9 | EP-104GI: Eupraxia Pharmaceuticals |
| 13 | Eosinophilic Esophagitis Market: 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Eosinophilic Esophagitis Market Outlook |
| 13.3 | Conjoint Analysis |
| 13.1 | Key Eosinophilic Esophagitis Market Forecast Assumptions |
| 13.2 | Total Market Size of EOE in the 7MM |
| 13.3 | Total Market Size of EOE by Therapies in the 7MM |
| 13.4 | The United States Eosinophilic Esophagitis Market |
| 13.4.1 | Total Market Size of EOE in the United States |
| 13.4.2 | Total Market Size of EOE by Therapies in the United States |
| 13.5 | EU4 and the UK Eosinophilic Esophagitis Market |
| 13.6 | Japan Eosinophilic Esophagitis Market |
| 14 | Unmet Needs of Eosinophilic Esophagitis |
| 15 | SWOT Analysis of Eosinophilic Esophagitis |
| 16 | KOL Views of Eosinophilic Esophagitis |
| 16.1 | Expert/KOL Interview Highlights |
| 17 | Market Access and Reimbursement of Eosinophilic Esophagitis |
| 17.1 | The US |
| 17.2 | In EU4 and the UK |
| 17.3 | Japan |
| 17.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
| 17.5 | Market Access and Reimbursement of EoE Therapies |
| 18 | Bibliography |
| 19 | Eosinophilic Esophagitis Market Report Methodology |
Related Reports
Eosinophilic Esophagitis Epidemiology
Eosinophilic Esophagitis Epidemiology Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted EoE epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Eosinophilic Esophagitis Clinical Trial Analysis Pipeline
Eosinophilic Esophagitis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic esophagitis companies, including Sanofi, Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion, Quorum Innovations, Serpin Pharma, RAPT Therapeutics, and others.
Eosinophilic Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic disorder companies including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, and others.
Eosinophilic Disorder Clinical Trial Analysis
Eosinophilic Disorder Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic disorder companies, including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, and others.
Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
